Mark Socinski, MD and Joshua Sabari, MD, share their insight for community oncologists who treat patients with KRASG12C-mutated NSCLC with CNS metastases.
Patritumab Deruxtecan Elicits Clinical Activity in Some Patients With Lung and Breast Cancer
March 20th 2023Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.
Read More
Clinicians Must Address Unusual AEs of BRAF/MEK Inhibition for BRAF-Mutated NSCLC
March 17th 2023A case report published in The Journal of the National Comprehensive Cancer Center highlights the importance of being mindful of unusual adverse events associated with BRAF/MEK inhibition for patients with BRAF-mutated non–small cell lung cancer.
Read More
Phase 1b/2a Trial of Bemcentinib and SOC Doses First Patient With STK11m NSCLC
March 11th 2023A phase 1b/2a trial is investigating the combination of bemcentinib with pembrolizumab and doublet chemotherapy in patients with first-line non–small cell lung cancer that harbors STK11 mutations.
Read More
2 Clarke Drive
Cranbury, NJ 08512